SCHEMBL14770568

SCHEMBL14770568

CCOc1ccc2[nH]c(C(C)c3ccc(OCc4ccccc4)cc3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
CYP3A4 P08684 3/20 0.43
KDM4E B2RXH2 3/20 0.42
HSD17B10 Q99714 3/20 0.42
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
NPC1 O15118 1/20 0.42
USP2 O75604 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
RAB9A P51151 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP2C9 P11712 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770573 0.90 MEN1 (0.46) MEN1HTTKMT2ANPC1RAB9A
SCHEMBL14770605 0.89 MEN1 (0.46) MEN1HTTKMT2AKDM4EHSD17B10
SCHEMBL14770571 0.89 KMT2A (0.46) MEN1HTTKMT2AMAPTACHE
SCHEMBL14770587 0.89 MEN1 (0.46) MEN1HTTKMT2ANPC1RAB9A
SCHEMBL14770580 0.89 FFAR1 (0.46) MEN1HTTKMT2AKDM4ELMNA
SCHEMBL14770595 0.89 MAOA (0.44) MEN1HTTKMT2ACYP3A4LMNA
SCHEMBL14770548 0.89 FFAR1 (0.44) MEN1HTTKMT2ACYP3A4KDM4E
SCHEMBL14770601 0.88 PTGES (0.51) MEN1HTTKMT2AKDM4EHSD17B10
SCHEMBL12065253 0.87 MEN1 (0.43) MEN1HTTKMT2ACYP3A4KDM4E
SCHEMBL14770579 0.86 CYP1A2 (0.46) MEN1HTTKMT2ACYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MEN1 2676/4885HTT 3959/4885KMT2A 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.